Perioperative Tislelizumab Preserves Quality of Life and Eases Chest Pain, Cough in NSCLC
This prespecified patient-reported outcome analysis of RATIONALE-315 shows whether adding perioperative anti-PD-1 therapy to neoadjuvant chemotherapy costs patients symptom burden or function in resectable stage II–IIIA non-small cell lung cancer (NSCLC).
📅 Journal publication: Oct 2026(online Nov 6, 2026)·Last updated: Nov 19, 2026
Tislelizumab improves lung cancer patients' quality of life by reducing symptoms.
This study evaluates patient-reported outcomes (PROs) in the use of tislelizumab plus chemotherapy for resectable NSCLC, highlighting its impact on quality of life measures. Patients receiving tislelizumab showed less chest pain and improved coughing than those on placebo, with significant differences observed during adjuvant therapy. While promising, the study is specific to perioperative treatment settings and focused on PROs, not directly altering current pharmacy practice yet. Tislelizumab plus chemotherapy shows benefits in managing symptoms like chest pain and coughing in resectable NSCLC.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Yue D, Cappuzzo F, Wang W, Liu H, Chen Q, Wang S, Leaw SJ, Yao B, Barnes FB, Barnes G, Wang C
Citation:Yue D, Cappuzzo F, Wang W, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial. Future oncology (London, England). 2026;22(24):2911-2921. doi:10.1080/14796694.2026.2743385